Lung Cancer

Lung Cancer is a type of cancer that begins in the lungs (two spongy organs in your chest that take in oxygen when you inhale and release carbon dioxide when you exhale).

When you breathe in, air enters through your mouth or nose and goes into your lungs through the trachea (windpipe). The trachea divides into tubes called bronchi (singular, bronchus), which enter the lungs and divide into smaller bronchi. These divides to form smaller branches called bronchioles. At the end of the bronchioles are tiny air sacs known as alveoli.

The alveoli absorb oxygen from the inhaled air into your blood and remove carbon dioxide from the blood. This is expelled from the body when you exhale. Taking in oxygen and getting rid of carbon dioxide are your lungs’ main functions.

Lung Cancers typically start in the cells lining the bronchi and parts of the lung such as the bronchioles or alveoli.

Types of Lung Cancer

Doctors divide Lung Cancer into two major types based on the appearance of Lung Cancer cells under the microscope, such as:

  • Non-Small Cell Lung Cancer (NSCLC): type that is encompassing several types of Lung Cancers that behave in a similar way, that includes:
    • Squamous Cell Carcinoma
    • Adenocarcinoma
    • Large Cell Carcinoma.
  • Small Cell Lung Cancer (SCLC): type that occurs almost exclusively in heavy smokers and is less common than Non-Small Cell Lung Cancer.

Risk Factors

Several of factors may increase your risk of Lung Cancer. Some risk factors can be managed, for instance, by quitting smoking, but other factors can’t be controlled, such as family history.

Risk factors for Lung Cancer include:

  • Tobacco smoke
  • Exposure to second-hand smoke
  • Exposure to radon gas
  • Exposure to asbestos and other carcinogens
  • Family history of Lung Cancer
  • Radioactive ores such as uranium
  • Inhaled chemicals or minerals such as arsenic, beryllium, cadmium, silica, vinyl chloride, nickel compounds, chromium compounds, coal products, mustard gas, and chloromethyl ethers
  • Air pollution
  • Radiation therapy to the lungs
  • Arsenic in drinking water

Symptoms and Signs

Although most Lung Cancers do not cause any symptoms until they have spread too far to be cured (Lung Cancer is one of cancers known as “silent cancers”), some people with early Lung Cancer may have any of next symptoms:

  • A cough that does not go away or gets worse
  • Chest pain that is often worse with deep breathing, coughing, or laughing
  • Hoarseness
  • Weight loss and loss of appetite
  • Coughing up blood or rust-colored sputum (spit or phlegm)
  • Shortness of breath
  • Feeling tired or weak
  • Infections such as bronchitis and pneumonia that don’t go away or keep coming back
  • New onset of wheezing
  • Horner syndrome
  • Superior vena cava syndrome
  • Paraneoplastic syndromes


Lung Cancer mainly occurs in older people. About 2 out of 3 people diagnosed with Lung Cancer are 65 or older, while less than 2% are younger than 45. The average age at the time of diagnosis is about 70. People presenting at stage I have the highest survival (35%). Survival is lower for those diagnosed with stage III disease (6%). Stage IV survival could not be calculated at five years due to the small number of people surviving more than two years. Survival for those people with stage not known is similar to those with stage III disease (6%).

Lung Cancer Diagnosis

Early diagnosis in cancer is very important because when it is diagnosed in early stage, before it’s had the chance to get too big or spread, it is more likely to be treated successfully. If the cancer has spread, treatment becomes more difficult, and generally a person’s chances of surviving are much lower.

As shown in the chart below, when Lung Cancer is detected early, 54% of patients survive for 5 years or more, but because this type of cancer has no early symptoms, usually detected when the cancer has already spread and the chances of survival are slim. In this regard, 85% of Lung Cancers are diagnosed at later stages (stages IIIA, IIIB and IV).

Diagnostic Stage vs Survival Rate at 5 years in Lung Cancer

State of the Art

Currently, doctors consider age and smoking habits of patients with symptoms such as the two main factors to model the risk of Lung Cancer.

If patients fall into this consideration, it is recommended a system based on a computerized tomography (CT) ―a test with a high cost that sometimes detected benign nodules as potentially cancerous―. Approximately 28 percent of high-risk individuals who are subjected to CT scans obtained a positive finding, since the test often identifies all existing pulmonary nodules.

However, 97 percent of lung nodules are not cancer ― the Lung nodules can be caused by a long list of diseases, both infectious and fungal infection, tuberculosis (TB), abscesses of lung or pneumonia; and non-infectious, such as rheumatoid arthritis (RA), Wegener’s granulomatosis or Sarcoidosis―. Moreover, 25 percent of suspicious nodules are benign, meaning that 1 of 4 individuals with nodule and suspicion of cancer is not).

Then, because these procedures are inherently limited to a mass or nodule finding, without providing critical molecular information in order to discriminate between malignant from benign, it is needed a biopsy to confirm, with certain related problems: first of all, the added risk and stress associated with biopsy can be hard on patients; secondly, for those patients with advanced or inaccessible cancers, biopsy may not be an option; and finally, all these procedures add significant costs over the course of treatment.

In this way, an analysis of cost/effectiveness published on November 6, 2014 in the New England Journal of Medicine ( from data from the National Lung Screening Trial (NLST) estimated that the costs of a computed tomography were $1,631 per person and $ 81,000 per year of life gained adjusted for quality.

Diagnosis Revolution

Here is where our solution can help by being an innovative, non-invasive, accurate, and cost-effective diagnosis solution, based in a simple blood test that can detect Lung Cancer with 93.5% of sensibility and 96.2% of specificity, while reduces ―in a very significantly way―, the number of false positives (FP) and false negatives (FN) typical of other diagnosis procedures.

If do you want to read more about our MBDAA for Lung Cancer Dx, please click on next button:


MBDAA for Lung Cancer Dx